| Literature DB >> 23530976 |
Michael A Hunt1, Courtney L Pollock, Virginia Byers Kraus, Tore Saxne, Sue Peters, Janet L Huebner, Eric C Sayre, Jolanda Cibere.
Abstract
BACKGROUND: Little is known about the relationships of circulating levels of biomarkers of cartilage degradation with biomechanical outcomes relevant to knee osteoarthritis (OA) or biomarker changes following non-pharmacological interventions. The objectives of this exploratory, pilot study were to: 1) examine relationships between biomarkers of articular cartilage degradation and synthesis with measures of knee joint load during walking, and 2) examine changes in these biomarkers following 10 weeks of strengthening exercises.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23530976 PMCID: PMC3623736 DOI: 10.1186/1471-2474-14-115
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Study participant flowchart.
Mean (SD) values for KAM and strength outcomes as well as for log-transformed, unadjusted biomarker levels and ratios of degradation to synthesis (sCPII) at baseline and follow-up for each group
| | | | | | | |
| Peak KAM (%BW*ht) | 3.75 (0.91) | 3.38 (0.78) | 3.70 (0.91) | 3.21 (0.95) | 0.04 (-0.64, 0.72) | 0.91 |
| KAM impulse (%BW*ht*sec) | 1.13 (0.40) | 1.32 (0.41) | 1.01 (0.35) | 1.24 (0.55) | –0.05 (–0.23, 0.32) | 0.72 |
| Walking speed (m/s) | 1.18 (0.23) | 1.03 (0.17) | 1.28 (0.18) | 1.04 (0.16) | 0.08 (–0.02, 0.18) | 0.11 |
| | | | | | | |
| Knee extension torque (Nm/kg) | 1.25 (0.34) | 0.98 (0.25) | 1.35 (0.39) | 0.97 (0.23) | 0.10 (–0.25, 0.06) | 0.19 |
| Knee flexion torque (Nm/kg) | 1.06 (0.33) | 0.82 (0.29) | 1.12 (0.35) | 0.70 (0.48) | 0.18 (–0.41, 0.06) | 0.12 |
| Hip abduction torque (Nm/kg) | 0.78 (0.19) | 0.59 (0.26) | 0.87 (0.28) | 0.69 (0.13) | –0.02 (–0.14, 0.18) | 0.77 |
| | | | | | | |
| | | | | | | |
| uCTX-II (log ng/mmol creatinine) | 5.40 (0.81) | 5.97 (0.57) | 5.32 (0.93) | 6.25 (0.68) | –0.33 (–0.71, 0.04) | 0.11 |
| uC2C (log μg/mmol creatinine) | 2.45 (0.68) | 2.46 (0.76) | 2.57 (0.81) | 2.71 (0.58) | –0.10 (–0.35, 0.16) | 0.73 |
| | | | | | | |
| sHA (log U/L) | 3.47 (0.93) | 3.80 (0.96) | 3.26 (1.13) | 4.21 (0.86) | –0.79 (–1.67, 0.08) | 0.10 |
| sCOMP (log U/L) | 2.20 (0.21) | 2.26 (0.17) | 2.11 (0.24) | 2.36 (0.13) | –0.16 (–0.30,–0.02) | 0.04 |
| sCPII (log U/L) | 6.56 (0.19) | 6.44 (0.53) | 6.50 (0.36) | 6.71 (0.40) | –0.34 (–0.94, 0.24) | 0.27 |
| | | | | | | |
| uCTX-II:sCPII | –1.16 (0.74) | –0.46 (0.49) | –1.18 (0.97) | –0.46 (0.81) | 0.01 (–0.63, 0.66) | 0.97 |
| uC2C:sCPII | –4.11 (0.69) | –3.98 (1.19) | –3.93 (0.98) | –4.01 (0.73) | 0.22 (–0.59, 1.03) | 0.61 |
| sHA:sCPII | –3.09 (0.99) | –2.64 (0.87) | –3.24 (1.37) | –2.50 (0.77) | –0.45 (–1.43, 0.53) | 0.39 |
Group comparisons (exercise – no exercise) denote the difference in mean change (95% CIs). Between-group mean differences for gait and strength data are unadjusted, while biomarker data for each log-transformed biomarker and ratio using linear regression modeling while adjusting for age and sex. Note that negative log-transformed values indicate that the absolute ratio was less than 1.0, with greater negative values indicating a smaller ratio of the degradation biomarker to the synthesis biomarker sCPII. Thus, improvements in the ratio of degradation to synthesis would be reflected in smaller negative values at follow-up.